ERBB2 and breast carcinoma: In our study, neoadjuvant chemotherapy combined with immunotherapy was applied for treatment with the achievement of certain therapeutic benefit, which can improve the clinical curative effect, enhance the immune function, and reduce the positive expression rate of ER, HER-2 and SATB1 in patients with HER-2-positive breast cancer.